Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Melody Trexler-Schmidt
Advertisement
Melody Trexler-Schmidt is a scientist in late-stage purification at Genentech, Inc.
Articles by Melody Trexler-Schmidt
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
